Co-Diagnostics, Inc. (CODX) News
Filter CODX News Items
CODX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CODX News Highlights
- For CODX, its 30 day story count is now at 2.
- Over the past 28 days, the trend for CODX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CODX are DX, CM and APP.
Latest CODX News From Around the Web
Below are the latest news stories about CO-DIAGNOSTICS INC that investors may wish to consider to help them evaluate CODX as an investment opportunity.
Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR ProCo-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has submitted its Co-Dx™ PCR COVID-19 test with Co-Dx PCR Pro™ instrument for review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA). The submission includes the PCR Pro instrument, COVID-19 detection test, and mobile app, all designed for use in point-of- |
Co-Diagnostics, Inc. to Participate in the Piper Sandler 35th Annual Healthcare Conference in New York City on November 30, 2023Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the Piper Sandler 35th Annual Healthcare Conference in New York City, New York on November 30, 2023. |
Co-Diagnostics, Inc. (NASDAQ:CODX) Q3 2023 Earnings Call TranscriptCo-Diagnostics, Inc. (NASDAQ:CODX) Q3 2023 Earnings Call Transcript November 9, 2023 Co-Diagnostics, Inc. beats earnings expectations. Reported EPS is $-0.2, expectations were $-0.29. Operator: Hello. Welcome to the Co-Diagnostics Third Quarter 2023 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note today’s event is being recorded. I would now like […] |
Q3 2023 Co-Diagnostics Inc Earnings CallQ3 2023 Co-Diagnostics Inc Earnings Call |
Co-Diagnostics, Inc. Reports Third Quarter 2023 Financial ResultsCo-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2023. |
Co-Diagnostics, Inc. Announces Additional Grant Award for Tuberculosis Test in DevelopmentCo-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced a grant awarded by the Bill & Melinda Gates Foundation to support the tuberculosis (TB) test in development, designed to be run on the upcoming Co-Dx™ PCR platform*. The amount awarded is $8.976 million. |
Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for November 2023Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the list of events it has chosen to exhibit at or attend during November, 2023, which strategically align with its mission of increasing accessibility of affordable gold-standard PCR diagnostics around the world. |
Co-Diagnostics, Inc. Announces Third Quarter 2023 Earnings Release Date and WebcastCo-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2023 results on Thursday, November 9, 2023, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts and institutional investors. Management on the call will include Dwight Egan, Chief Executive |
Co-Diagnostics, Inc. to Host Booth at CASMET Symposium October 23-25Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth this week at the Caribbean Association of Medical Technologies (CASMET) Scientific Symposium and BGM, held in Barbados October 22-26, 2023. |
Co-Diagnostics, Inc. to Host Booth at Medlab Africa 2023 in Johannesburg, South AfricaCo-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth this week at Africa Health/Medlab Africa in Johannesburg, South Africa on October 17-19, 2023. |